Niki Katsiki

Niki Katsiki serves as an Adjunct Research Assistant Professor at Aristotle University of Thessaloniki's Medical School, affiliated with the Department of Diabetes, Endocrinology and Metabolism at AHEPA Hospital in Thessaloniki, Greece. Her clinical and research activities focus on the intersection of lipid metabolism, diabetes complications, and cardiovascular risk management.

Her academic foundation includes:

• Medicine Degree (2003), Aristotle University of Thessaloniki Medical School
• Postgraduate Degree (2006), Aristotle University of Thessaloniki Medical School
• Doctoral Degree (2011), Aristotle University of Thessaloniki Medical School

Dr. Katsiki's research spans lipidology, diabetes therapeutics, obesity pharmacology, and cardiometabolic risk prediction. She investigates molecular mechanisms like fibroblast growth factor 21's role in cardiovascular disease, evaluates novel anti-obesity agents such as semaglutide, and examines gender-specific considerations in interventional cardiology. Her work frequently addresses clinical translation of lipid-lowering therapies and their impact on vascular function.

Analysis of her recent publications reveals a cohesive focus on clinical pharmacology in cardiometabolic medicine, characterized by systematic reviews of lipid-modifying drugs, investigations into lipoprotein(a) management, and evaluations of drug safety profiles in high-risk populations. Her collaborative approach spans international consortia with recurring themes of evidence-based risk reduction.

Her scientific recognition includes:

• Excellence Scholarship from Aristotle University of Thessaloniki Research Committee (2015)
• Best Oral Presentation Award from Diabetes Society of Northern Greece (2009)
• Best Poster Presentation Award from Hellenic Diabetes Society (2009)
• PhD Scholarship from Diabetes Society of Northern Greece (2008)

Dr. Katsiki actively contributes to clinical research through industry-sponsored trials, currently serving as lead researcher in three phase 3 lipid-lowering drug studies, an ongoing observational dyslipidemia study, and a type 2 diabetes observational project. She also provides academic leadership as a continuous Board Member of the Hellenic Atherosclerosis Society since 2017, influencing national guidelines for cardiovascular risk management.

Her current work integrates hospital-based clinical practice at AHEPA Hospital with academic research initiatives, maintaining active collaborations with international consortia focused on diabetes complications and lipidology while mentoring junior researchers through the university's medical education programs.